Photo taken from The START Center for Cancer Research/LinkedIn
Aug 17, 2024, 19:53
First European Patient Dosed in Phase I Trial Of Novel CD30-Directed ADC FOR Lymphomas – The START Center for Cancer Research
“We are thrilled to announce that we have dosed the first European patient in the Phase 1, open-label, multicenter study exploring a novel CD30-directed antibody-drug conjugate in patients with various relapsed/refractory lymphomas, including T-cell lymphoma, classical Hodgkin lymphoma and diffuse large B-cell lymphoma at START Madrid-FJD.
This enrollment and dosing milestone is a significant step forward in our mission to advance innovative treatments in oncology, where we hope to address an unmet medical need for this patient population.
We are proud to lead this effort and look forward to the hope this investigational therapy will bring to patients across Europe.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 20, 2025, 20:33
Jan 20, 2025, 20:31
Jan 20, 2025, 20:26
Jan 20, 2025, 20:21
Jan 20, 2025, 20:12
Jan 20, 2025, 20:10
Jan 20, 2025, 20:08
Jan 20, 2025, 20:06
Jan 20, 2025, 20:03